Literature DB >> 33012445

Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma.

Tracey G Simon1, Andrew T Chan2.   

Abstract

Patients with chronic liver disease are at increased risk of developing hepatocellular carcinoma (HCC). Most patients diagnosed with HCC have limited treatment options and a poor overall prognosis, with a 5-year survival less than 15%. Preventing the development of HCC represents the most important strategy. However, current guidelines lack specific recommendations for primary prevention. Lifestyle factors may be central in the pathogenesis of HCC, and primary prevention strategies focused on lifestyle modification could represent an important approach to the prevention of HCC. Both experimental and epidemiologic studies have identified promising chemopreventive agents for the primary prevention of HCC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer prevention; Chemoprevention; Hepatocellular carcinoma; Lifestyle; Modifiable risk factor

Year:  2020        PMID: 33012445      PMCID: PMC7536356          DOI: 10.1016/j.cld.2020.06.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  199 in total

1.  Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  Liver Int       Date:  2018-06-29       Impact factor: 5.828

2.  High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.

Authors:  Hannes Hagström; Per Tynelius; Finn Rasmussen
Journal:  Gut       Date:  2017-03-20       Impact factor: 23.059

Review 3.  Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis.

Authors:  Huiling Sun; Qiwen Deng; Yuqin Pan; Bangshun He; Houqun Ying; Jie Chen; Xian Liu; Shukui Wang
Journal:  J BUON       Date:  2015 Jan-Feb       Impact factor: 2.533

4.  Failure rates in the hepatocellular carcinoma surveillance process.

Authors:  Amit G Singal; Adam C Yopp; Samir Gupta; Celette Sugg Skinner; Ethan A Halm; Eucharia Okolo; Mahendra Nehra; William M Lee; Jorge A Marrero; Jasmin A Tiro
Journal:  Cancer Prev Res (Phila)       Date:  2012-07-30

5.  Vegetable-based dietary pattern and liver cancer risk: results from the Shanghai women's and men's health studies.

Authors:  Wei Zhang; Yong-Bing Xiang; Hong-Lan Li; Gong Yang; Hui Cai; Bu-Tian Ji; Yu-Tang Gao; Wei Zheng; Xiao-Ou Shu
Journal:  Cancer Sci       Date:  2013-08-05       Impact factor: 6.716

Review 6.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

7.  Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.

Authors:  Xinke Zhou; Jitao Chen; Gao Yi; Min Deng; Hao Liu; Min Liang; Boyun Shi; Xin Fu; Yuqin Chen; Liangcai Chen; Zhimin He; Jian Wang; Jifang Liu
Journal:  Oncotarget       Date:  2016-01-05

8.  Plasma Amino Acid Concentrations Predict Mortality in Patients with End-Stage Liver Disease.

Authors:  Benedict Kinny-Köster; Michael Bartels; Susen Becker; Markus Scholz; Joachim Thiery; Uta Ceglarek; Thorsten Kaiser
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

9.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.

Authors:  Tomi Akinyemiju; Semaw Abera; Muktar Ahmed; Noore Alam; Mulubirhan Assefa Alemayohu; Christine Allen; Rajaa Al-Raddadi; Nelson Alvis-Guzman; Yaw Amoako; Al Artaman; Tadesse Awoke Ayele; Aleksandra Barac; Isabela Bensenor; Adugnaw Berhane; Zulfiqar Bhutta; Jacqueline Castillo-Rivas; Abdulaal Chitheer; Jee-Young Choi; Benjamin Cowie; Lalit Dandona; Rakhi Dandona; Subhojit Dey; Daniel Dicker; Huyen Phuc; Donatus U. Ekwueme; Maysaa El Sayed Zaki; Florian Fischer; Thomas Fürst; Jamie Hancock; Simon I. Hay; Peter Hotez; Sun Ha Jee; Amir Kasaeian; Yousef Khader; Young-Ho Khang; Anil Kumar; Michael Kutz; Heidi Larson; Alan Lopez; Raimundas Lunevicius; Reza Malekzadeh; Colm McAlinden; Toni Meier; Walter Mendoza; Ali Mokdad; Maziar Moradi-Lakeh; Gabriele Nagel; Quyen Nguyen; Grant Nguyen; Felix Ogbo; George Patton; David M. Pereira; Farshad Pourmalek; Mostafa Qorbani; Amir Radfar; Gholamreza Roshandel; Joshua A Salomon; Juan Sanabria; Benn Sartorius; Maheswar Satpathy; Monika Sawhney; Sadaf Sepanlou; Katya Shackelford; Hirbo Shore; Jiandong Sun; Desalegn Tadese Mengistu; Roman Topór-Mądry; Bach Tran; Vasiliy Vlassov; Stein Emil Vollset; Theo Vos; Tolassa Wakayo; Elisabete Weiderpass; Andrea Werdecker; Naohiro Yonemoto; Mustafa Younis; Chuanhua Yu; Zoubida Zaidi; Liguo Zhu; Christopher J. L. Murray; Mohsen Naghavi; Christina Fitzmaurice
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

10.  Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.

Authors:  S Kato; S Smalley; A Sadarangani; K Chen-Lin; B Oliva; J Brañes; J Carvajal; R Gejman; G I Owen; M Cuello
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

View more
  2 in total

1.  Distinguishing Hepatocellular Carcinoma From Hepatic Inflammatory Pseudotumor Using a Nomogram Based on Contrast-Enhanced Ultrasound.

Authors:  Mengting Liao; Chenshan Wang; Bo Zhang; Qin Jiang; Juan Liu; Jintang Liao
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

2.  Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study.

Authors:  Fung-Chang Sung; Yi-Ting Yeh; Chih-Hsin Muo; Chih-Cheng Hsu; Wen-Chen Tsai; Yueh-Han Hsu
Journal:  Cancers (Basel)       Date:  2022-02-06       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.